Cargando…
Ceftriaxone-induced hemolysis
Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793531/ https://www.ncbi.nlm.nih.gov/pubmed/24130395 http://dx.doi.org/10.4103/0253-7613.117758 |
_version_ | 1782477833603383296 |
---|---|
author | Guleria, Vivek S. Sharma, Nitin Amitabh, Sagar Nair, Velu |
author_facet | Guleria, Vivek S. Sharma, Nitin Amitabh, Sagar Nair, Velu |
author_sort | Guleria, Vivek S. |
collection | PubMed |
description | Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped from 9.6 g /dl to 5.5 g /dl. However, she improved after discontinuation of the drug and blood transfusion. This report serves as a reminder to medical fraternity that life-threatening hemolysis can rarely follow administration of ceftriaxone. |
format | Online Article Text |
id | pubmed-3793531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-37935312013-10-15 Ceftriaxone-induced hemolysis Guleria, Vivek S. Sharma, Nitin Amitabh, Sagar Nair, Velu Indian J Pharmacol Drug Watch Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped from 9.6 g /dl to 5.5 g /dl. However, she improved after discontinuation of the drug and blood transfusion. This report serves as a reminder to medical fraternity that life-threatening hemolysis can rarely follow administration of ceftriaxone. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3793531/ /pubmed/24130395 http://dx.doi.org/10.4103/0253-7613.117758 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Drug Watch Guleria, Vivek S. Sharma, Nitin Amitabh, Sagar Nair, Velu Ceftriaxone-induced hemolysis |
title | Ceftriaxone-induced hemolysis |
title_full | Ceftriaxone-induced hemolysis |
title_fullStr | Ceftriaxone-induced hemolysis |
title_full_unstemmed | Ceftriaxone-induced hemolysis |
title_short | Ceftriaxone-induced hemolysis |
title_sort | ceftriaxone-induced hemolysis |
topic | Drug Watch |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793531/ https://www.ncbi.nlm.nih.gov/pubmed/24130395 http://dx.doi.org/10.4103/0253-7613.117758 |
work_keys_str_mv | AT guleriaviveks ceftriaxoneinducedhemolysis AT sharmanitin ceftriaxoneinducedhemolysis AT amitabhsagar ceftriaxoneinducedhemolysis AT nairvelu ceftriaxoneinducedhemolysis |